Evidence map›Paper›PMID 41965070›Full record

SynthesisRheumatology (Oxford, England)2026

Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon.

Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, Carlos Rosa-Baez, Martin Kerick, Alfredo Guillén-Del-Castillo, Carmen P Simeón-Aznar, José L Callejas, Oliver Distler, Susanna M Proudman, Mandana Nikpour and 14 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Carlos Rangel-PeláezInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0001-7697-1696
Inmaculada Rodriguez-MartinInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0001-5413-1581
Carlos Rosa-BaezInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0002-1257-3338
Martin KerickInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0002-6298-4514
Alfredo Guillén-Del-CastilloSystemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-0626-507X
Carmen P Simeón-AznarSystemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-3390-9029
José L CallejasSystemic Autoimmune Disease Unit, Hospital Clínico San Cecilio, Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain.ORCID 0000-0002-1653-0087
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Susanna M ProudmanRheumatology Unit, Royal Adelaide Hospital and the University of Adelaide, Adelaide, South Australia, Australia.ORCID 0000-0002-3046-9884
Mandana NikpourDepartment of Medicine, University of Melbourne, Fitzroy, Victoria, Australia.ORCID 0000-0002-6585-5611
Nicolas HunzelmannDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
Gianluca MoronciniDepartment of Clinical and Molecular Science, Marche Polytechnic University, Ancona, Italy.ORCID 0000-0002-0380-0105
Jeska K de Vries-BouwstraThe Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-5624-1415
Ariane L HerrickDivision of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0003-4941-7926
Yannick AllanoreDepartment of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France.ORCID 0000-0002-6149-0002
Marta E Alarcón-RiquelmeCentre for Genomics and Oncological Research, Pfizer, University of Granada/Andalusian Regional Government, Spain, Granada.ORCID 0000-0002-7632-4154
Lorenzo BerettaScleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.ORCID 0000-0002-6529-6258
Maureen D MayesUT Health Houston, Division of Rheumatology, McGovern Medical School, Houston, TX, USA.ORCID 0000-0001-5070-2535
Christopher P DentonCentre for Rheumatology, Royal Free Hospital, UCL, London, UK.ORCID 0000-0003-3975-8938
Shervin AssassiUT Health Houston, Division of Rheumatology, McGovern Medical School, Houston, TX, USA.ORCID 0000-0002-8059-9978
Javier MartínInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0002-2202-0622
Marialbert Acosta-HerreraInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0002-9868-6535
Lourdes Ortiz-FernándezInstitute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.ORCID 0000-0002-0247-4280
and the International SSc Group, the PRECISESADS Clinical Consortium, and the Australian Scleroderma Interest Group (ASIG)#

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRaynaud's phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc.

methodsWe analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications.

resultsBeyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10-2).

conclusionThis study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies.

Indexed as

Genetic PleiotropyRaynaud DiseaseScleroderma, SystemicGenetic Predisposition to DiseaseGenetic Risk ScoreGenome-Wide Association StudyHumansPolymorphism, Single Nucleotidecross-traitGWASMEOX2polygenic risk scoreRaynaud’s phenomenonsystemic sclerosis

Identifiers

PMID41965070
PMCPMC13171172

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.